Journal
CANCER CELL INTERNATIONAL
Volume 9, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/1475-2867-9-5
Keywords
-
Categories
Funding
- Inserm
- Ligue nationale contre le cancer
- Association pour la recherche sur le cancer [3161]
- Institut national du cancer [PL2008]
Ask authors/readers for more resources
Alterations of receptor-type tyrosine kinases (RTK) are frequent in human cancers. They can result from translocation, mutation or amplification. The ERBB2 RTK is encoded by a gene that is amplified in about 20% breast cancers. The question is: why is this RTK specifically subjected to this type of alteration? We propose that ERBB2 gene amplification is used to overcome repression of its expression by sequence-specific transcription factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
